Eczema: About, Causes, Solutions
About Eczema
Eczema is an umbrella term encompassing several inflammatory skin disorders, the most common of which is atopic dermatitis. Other clinically recognized variants include contact dermatitis (allergic and irritant subtypes), dyshidrotic eczema, nummular eczema, seborrheic dermatitis, and stasis dermatitis. While each presents with distinct clinical features and triggers, all share a common feature: a compromised epidermal barrier coupled with an exaggerated inflammatory response.
Clinically, eczema typically presents as dry, scaly, intensely pruritic patches of skin that may appear erythematous, vesicular, weeping, lichenified, or hyperpigmented depending on chronicity and skin phototype. Distribution varies by age — infants commonly present with facial and extensor involvement, while older children and adults tend to exhibit flexural involvement at the antecubital and popliteal fossae, neck, and hands. The condition follows a relapsing-remitting course, with periods of flare and quiescence often influenced by environmental, immunologic, and psychological factors.
Causes
The pathogenesis of eczema is multifactorial, governed by an interplay of genetic, immunologic, and environmental mechanisms:
The first is epidermal barrier dysfunction, often driven by loss-of-function mutations in the filaggrin (FLG) gene, which encodes a structural protein essential for maintaining stratum corneum integrity and hydration. A compromised barrier permits transepidermal water loss and increases susceptibility to allergens, irritants, and microbial colonization. The second is immune dysregulation, characterized by a predominant Th2-mediated inflammatory response and elevated cytokines such as IL-4, IL-13, IL-31, and TSLP, which drive itch, inflammation, and further barrier disruption. The third is microbial dysbiosis, particularly cutaneous overgrowth of Staphylococcus aureus, which exacerbates inflammation and may trigger flares through superantigen production.
Secondary contributing factors include genetic predisposition (personal or family history of atopy, asthma, or allergic rhinitis), environmental allergens (dust mites, pet dander, pollen), irritants (soaps, detergents, fragrances, wool), climatic extremes (low humidity, excessive heat), psychological stress, hormonal fluctuations, and food sensitivities in a subset of pediatric patients. Recent research has also highlighted the role of the gut–skin axis and early-life microbiome development in disease predisposition.
Treatment
Effective eczema management is multimodal and individualized to severity, age, distribution, and trigger profile. Therapy spans topical, systemic, and adjunctive categories, with patient education and barrier repair forming the foundation of all treatment plans.
Topical therapies are the mainstay for mild to moderate disease. Emollients and moisturizers, applied liberally and consistently, are first-line in all patients and serve to restore barrier function, reduce transepidermal water loss, and decrease flare frequency. Topical corticosteroids — selected by potency to match lesion severity and anatomical site — remain the most established anti-inflammatory agents for active flares. Topical calcineurin inhibitors (tacrolimus, pimecrolimus) provide a steroid-sparing option, particularly useful for sensitive areas such as the face, eyelids, and intertriginous regions. Newer topical agents include crisaborole (a PDE-4 inhibitor), ruxolitinib (a topical JAK inhibitor), and tapinarof, each offering targeted anti-inflammatory action with favorable safety profiles for long-term use.
Systemic therapies are indicated for moderate to severe, refractory, or widespread disease. Conventional immunosuppressants such as cyclosporine, methotrexate, azathioprine, and mycophenolate mofetil have historically been used, though their utility is limited by monitoring requirements and side-effect profiles. Biologic therapies have transformed the treatment landscape: dupilumab (anti–IL-4Rα), tralokinumab (anti–IL-13), and lebrikizumab selectively target Th2 cytokine pathways and offer substantial improvements in disease severity and quality of life. Oral JAK inhibitors — including upadacitinib, abrocitinib, and baricitinib — provide rapid symptom control through inhibition of cytokine signaling, with appropriate clinical monitoring.
Adjunctive interventions include phototherapy (narrowband UVB), wet wrap therapy during severe flares, bleach baths to reduce S. aureus colonization, and antihistamines for sleep support when pruritus disrupts rest. Patient and caregiver education on trigger avoidance, proper bathing practices, and consistent emollient use is integral to long-term success.
Solution
A durable solution to eczema is rarely a single intervention but rather a sustained, individualized regimen anchored in three principles: barrier repair, inflammation control, and trigger management.
Barrier repair begins with daily skincare habits — lukewarm (not hot) bathing using gentle, fragrance-free, syndet cleansers, followed within three minutes by liberal application of a ceramide-rich or occlusive emollient to lock in moisture. Inflammation control involves the appropriate, timely use of anti-inflammatory therapies during flares, with proactive maintenance therapy (intermittent topical anti-inflammatories on previously affected sites) shown to significantly reduce relapse frequency. Trigger management requires careful identification and avoidance of individual provocateurs — whether allergens, irritants, climate, or stressors — supported by allergy evaluation when clinically indicated.
Equally important are lifestyle considerations: maintaining a humidified indoor environment, wearing soft, breathable fabrics such as cotton, managing stress through behavioral and mindfulness-based interventions, ensuring adequate sleep, and supporting overall immune and skin health through balanced nutrition. Patients should be counseled that eczema is a chronic condition that may wax and wane over years, and that adherence to a preventive routine — even during clear periods — is the strongest predictor of long-term control.
With a structured, evidence-based approach, eczema is a highly manageable condition, and meaningful, sustained improvement in skin comfort, appearance, and quality of life is an achievable outcome for the vast majority of patients.
Products
Salix-B3 Clarifying Gel Cleanser Klärex
Active Ingredient:
Price:
R&D Phase ⓘ
Salix-B3 Clarifying Gel Cleanser Klärex
Active Ingredient:
Price: